|
Return to Contents in this
Issue |
|
Review |
|
|
|
Diagnostic Tests Based on Human
Basophils:
More Potentials and Perspectives Than
Pitfalls. II. Technical Issues |
|
|
|
AL De Weck,1 ML Sanz,1 PM Gamboa,2 W Aberer,3 J Bienvenu,4
M Blanca,7
P Demoly,5 DG Ebo,6 L Mayorga,7 G Monneret,4 J Sainte
Laudy8 |
|
1University of Navarra, Pamplona, Spain
2Hospital Basurto, Bilbao, Spain
3University of Graz, Graz, Austria
4Centre Hospitalier Universitaire, Lyon, France
5Centre Hospitalier Universitaire, Montpellier, France
6University Hospital, Antwerp, Belgium
7Carlos Haya Hospital, Malaga, Spain
8Centre Hospitalier Universitaire, Limoges, France |
|
J Investig Allergol Clin Immunol
2008; Vol. 18(3): 143-155 |
|
|
|
Abstract |
|
Cellular basophil
activation tests
(BAT) such as
histamine or
sulfidoleukotriene-release
tests for allergy
diagnosis have been
available for
some time, but
expression of
basophil-activation
markers such as CD63
and CD203c detected
by flow cytometry
has attracted
particular
attention in recent
years. Not only the
potential but also
the possible
pitfalls of
flow-cytometric BAT
have been stressed
recently. Some
authors have
suggested that the
technical problems
are still such that
BAT should only be
performed in
specialist
laboratories.
In an earlier review
based on our
clinical experience
obtained over
several years, we
showed that, even
using different
protocols,
reproducible
and meaningful
clinical results can
be obtained. In this
paper, we review the
current knowledge in
relation to several
technical issues and
show that
flow-cytometric BAT
already represents a
major advance in the
field of in vitro
allergy diagnosis.
We conclude that
there are
no serious technical
justifications for
depriving allergic
patients of
clinically indicated
BAT tests, which can
be performed
reliably by any
laboratory with the
appropriate
experience in
allergy diagnosis
and flow cytometry.
Key words:
Basophil activation
test. Allergy
diagnosis. CD63.
CD203c. Technical
issues.
|
|
|
|
| |
|
|
|
|
|
|
|
|
|
|